The first siRNA drug Onpattro (patisiran) targeting transthyretin (TTR) has been approved by the U.S. Food and Drug Administration (FDA) in 2018, for the treatment of peripheral nerve disease polyneuropathy in adults. This evidence concerns the gene TTR and polyneuropathy.